Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

Inclusion Criteria: * Clinical diagnosis of oral cavity squamous cell cancer. * Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within 7 days of registration in order to continue study agent administration. * Clinical stage II-IVA (as defined by the American Joint Committee on Cancer, 8th Edition \[see Amin, 2017\]) and amenable to surgical resection * New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of 6 months following previous definite surgery * History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration * Study agent administration should start within 7 days of registration * Patient must receive administration of study agent for a minimum of 7 days * Zubrod Score/Eastern Cooperative Oncology Group (ECOG) Performance status \< 2. * Age ≥ 18 years. * Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows: * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3; * Platelets ≥ 100,000 cells/mm\^3; * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.); * Adequate renal and hepatic function within 14 calendar days prior to registration, defined as follows: o Ser…